Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CORE LABORATORIES N VCLB · Entity 11862 | SVP, Gen Counsel & Secretary | February 16, 2023 | February 21, 2023 |
| Core Laboratories Inc. /DE/CLB · Entity 5382 | SVP, Gen Counsel & Secretary | October 01, 2026 | October 05, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CORE LABORATORIES N V
Report date February 16, 2023 · Filed February 21, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Performance SharesSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 21,418 |
Reported balance
After 2023-02-16 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-02-16 · Grant · Acquired 21,418 · Balance 21,418 F1: This award vests at the end of a three-year performance period that began on January 1, 2023 and ends on December 31, 2025 (the "Performance Period"). This award survives termination of employment due to death, disability, termination by the Company without cause or retirement by the employee upon having reached 62 years of age. In all cases, the shares will vest, if at all, at the end of the Performance Period as follows: 50% of the award will vest if the Company is in the top 35th percentile of Return on Invested Capital (ROIC) among the Bloomberg Peer Group (BPG), 100% of the award will vest if the Company is in the top 55th percentile of ROIC of the BPG, and 175% of the award will vest if the Company is in the top 85th percentile of ROIC of the BPG, as measured and determined by the Compensation Committee at the end of the Performance Period. F2: The number of common shares vesting pursuant to the award will be interpolated on a straight-line basis between the 35th and 55th percentile (equivalent to 50% up to 100% of the award) and again between the 55th and 85th percentile (equivalent to 100% up to 175% of the award). The number of common shares that could vest over 100% of the award up to the maximum of 175% of the award, if any, will be reduced by one-half if absolute total shareholder return for the Performance Period is negative, as measured and determined by the Compensation Committee at the end of the Performance Period. |
Filing footnotes · ownership attribution and instrument terms
F1: This award vests at the end of a three-year performance period that began on January 1, 2023 and ends on December 31, 2025 (the "Performance Period"). This award survives termination of employment due to death, disability, termination by the Company without cause or retirement by the employee upon having reached 62 years of age. In all cases, the shares will vest, if at all, at the end of the Performance Period as follows: 50% of the award will vest if the Company is in the top 35th percentile of Return on Invested Capital (ROIC) among the Bloomberg Peer Group (BPG), 100% of the award will vest if the Company is in the top 55th percentile of ROIC of the BPG, and 175% of the award will vest if the Company is in the top 85th percentile of ROIC of the BPG, as measured and determined by the Compensation Committee at the end of the Performance Period.
F2: The number of common shares vesting pursuant to the award will be interpolated on a straight-line basis between the 35th and 55th percentile (equivalent to 50% up to 100% of the award) and again between the 55th and 85th percentile (equivalent to 100% up to 175% of the award). The number of common shares that could vest over 100% of the award up to the maximum of 175% of the award, if any, will be reduced by one-half if absolute total shareholder return for the Performance Period is negative, as measured and determined by the Compensation Committee at the end of the Performance Period.
Core Laboratories Inc. /DE/
Report date October 01, 2026 · Filed October 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 28,088.621 |
Reported balance
After 2026-10-01 transaction · row 1
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 1 · 2026-10-01 · Tax withholding · Disposed 276 · Balance 28,088.621 |
| Common StockSEC Table I · non-derivative | Direct | 28,364.621 |
Reported balance
After 2026-10-01 transaction · row 2
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 2 · 2026-10-01 · Exercise / conversion · Acquired 700 · Balance 28,364.621 |
| Restricted SharesSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 250 |
Reported balance
After 2026-10-01 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-10-01 · Exercise / conversion · Disposed 700 · Balance 250 F1: The Restricted Shares vest annually over six years on the anniversary of the grant date in the amount specified in the award agreement, provided the reporting person remains in continuous service on each such vesting date. |
| Common StockSEC Table I · non-derivative | IndirectCustodial account | 20 |
Reported balance
Holding disclosure · report date 2026-10-01 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 20 |
| Common StockSEC Table I · non-derivative | Indirect401 (k) Plan | 1,694.842 |
Reported balance
Holding disclosure · report date 2026-10-01 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 1,694.842 |
Filing footnotes · ownership attribution and instrument terms
F1: The Restricted Shares vest annually over six years on the anniversary of the grant date in the amount specified in the award agreement, provided the reporting person remains in continuous service on each such vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 01, 2026 Filed Oct 5, 2026 16:18 UTC | Core Laboratories Inc. /DE/ CLB · Entity 5382 | Exercise / conversionRestricted Shares · Derivative | 700 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-413742 · ownership.xml · derivative · entry 5 Tattoli Mark Damian · CIK 0001872069 · SVP, Gen Counsel & Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 250 Underlying: Common Stock · 700 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The Restricted Shares vest annually over six years on the anniversary of the grant date in the amount specified in the award agreement, provided the reporting person remains in continuous service on each such vesting date. F1 · derivative.expiration_date: The Restricted Shares vest annually over six years on the anniversary of the grant date in the amount specified in the award agreement, provided the reporting person remains in continuous service on each such vesting date. Read SEC document |
| October 01, 2026 Filed Oct 5, 2026 16:18 UTC | Core Laboratories Inc. /DE/ CLB · Entity 5382 | Exercise / conversionCommon Stock | 700 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-413742 · ownership.xml · nonDerivative · entry 2 Tattoli Mark Damian · CIK 0001872069 · SVP, Gen Counsel & Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,364.621 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 01, 2026 Filed Oct 5, 2026 16:18 UTC | Core Laboratories Inc. /DE/ CLB · Entity 5382 | Tax withholdingCommon Stock | 276 | $9.76 | $2,693.76 |
DisclosureSEC source: 0001193125-26-413742 · ownership.xml · nonDerivative · entry 1 Tattoli Mark Damian · CIK 0001872069 · SVP, Gen Counsel & Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,088.621 Read SEC document |
| August 01, 2026 Filed Aug 4, 2026 14:27 UTC | Core Laboratories Inc. /DE/ CLB · Entity 5382 | Exercise / conversionRestricted Shares · Derivative | 250 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-331829 · ownership.xml · derivative · entry 5 Tattoli Mark Damian · CIK 0001872069 · SVP, Gen Counsel & Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 950 Underlying: Common Stock · 250 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The Restricted Shares vest annually over six years on the anniversary of the grant date in the amount specified in the award agreement, provided the reporting person remains in continuous service on each such vesting date. F1 · derivative.expiration_date: The Restricted Shares vest annually over six years on the anniversary of the grant date in the amount specified in the award agreement, provided the reporting person remains in continuous service on each such vesting date. F2 · balance_after: Multiple restricted share grants are included in this total. Read SEC document |
| August 01, 2026 Filed Aug 4, 2026 14:27 UTC | Core Laboratories Inc. /DE/ CLB · Entity 5382 | Exercise / conversionCommon Stock | 250 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-331829 · ownership.xml · nonDerivative · entry 2 Tattoli Mark Damian · CIK 0001872069 · SVP, Gen Counsel & Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,763.621 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 01, 2026 Filed Aug 4, 2026 14:27 UTC | Core Laboratories Inc. /DE/ CLB · Entity 5382 | Tax withholdingCommon Stock | 99 | $10.64 | $1,053.36 |
DisclosureSEC source: 0001193125-26-331829 · ownership.xml · nonDerivative · entry 1 Tattoli Mark Damian · CIK 0001872069 · SVP, Gen Counsel & Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,664.621 Read SEC document |
| May 01, 2026 Filed May 4, 2026 20:37 UTC | Core Laboratories Inc. /DE/ CLB · Entity 5382 | Exercise / conversionRestricted Shares · Derivative | 250 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-204136 · ownership.xml · derivative · entry 5 Tattoli Mark Damian · CIK 0001872069 · SVP, Gen Counsel & Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,200 Underlying: Common Stock · 250 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The Restricted Shares vest annually over six years on the anniversary of the grant date in the amount specified in the award agreement, provided the reporting person remains in continuous service on each such vesting date. F1 · derivative.expiration_date: The Restricted Shares vest annually over six years on the anniversary of the grant date in the amount specified in the award agreement, provided the reporting person remains in continuous service on each such vesting date. F2 · balance_after: Multiple restricted share grants are included in this total. Read SEC document |
| May 01, 2026 Filed May 4, 2026 20:37 UTC | Core Laboratories Inc. /DE/ CLB · Entity 5382 | Exercise / conversionCommon Stock | 250 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-204136 · ownership.xml · nonDerivative · entry 2 Tattoli Mark Damian · CIK 0001872069 · SVP, Gen Counsel & Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,610.621 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 01, 2026 Filed May 4, 2026 20:37 UTC | Core Laboratories Inc. /DE/ CLB · Entity 5382 | Tax withholdingCommon Stock | 97 | $14.07 | $1,364.79 |
DisclosureSEC source: 0001193125-26-204136 · ownership.xml · nonDerivative · entry 1 Tattoli Mark Damian · CIK 0001872069 · SVP, Gen Counsel & Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,513.621 Read SEC document |
| February 12, 2026 Filed Feb 17, 2026 16:07 UTC | Core Laboratories Inc. /DE/ CLB · Entity 5382 | GrantPerformance Shares · Derivative | 33,490 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-053614 · ownership.xml · derivative · entry 1 Tattoli Mark Damian · CIK 0001872069 · SVP, Gen Counsel & Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,490 Underlying: Common Stock · 33,490 shares Expires not disclosed F1 · derivative.exercise_date: This award vests following the conclusion of a three-year performance period that began on January 1, 2026 and ends on December 31, 2028 (the "Performance Period"). This award survives termination of employment due to death, disability, termination by the Company without cause or retirement by the employee upon having reached 62 years of age. In all cases, the shares will vest, if at all, on December 31, 2028, following the conclusion of the Performance Period as follows: 50% of the award will vest if the Company is in the top 35th percentile of Return on Invested Capital ("ROIC") among the Bloomberg Peer Group ("BPG"), 100% of the award will vest if the Company is in the top 55th percentile of ROIC among the BPG, and 175% of the award will vest if the Company is at or above the 85th percentile of ROIC among the BPG, as measured and determined by the Compensation Committee at the end of the Performance Period. F2 · derivative.exercise_date: The number of common shares vesting pursuant to the award will be interpolated on a straight-line basis between the 35th and 55th percentile of ROIC (equivalent to 50% up to 100% of the award) and again between the 55th and 85th percentile of ROIC (equivalent to 100% up to 175% of the award). The number of common shares that could vest over 100% of the award up to the maximum of 175% of the award, if any, will be reduced by one-half if absolute total shareholder return for the Performance Period is negative, as measured and determined by the Compensation Committee at the end of the Performance Period. F1 · derivative.expiration_date: This award vests following the conclusion of a three-year performance period that began on January 1, 2026 and ends on December 31, 2028 (the "Performance Period"). This award survives termination of employment due to death, disability, termination by the Company without cause or retirement by the employee upon having reached 62 years of age. In all cases, the shares will vest, if at all, on December 31, 2028, following the conclusion of the Performance Period as follows: 50% of the award will vest if the Company is in the top 35th percentile of Return on Invested Capital ("ROIC") among the Bloomberg Peer Group ("BPG"), 100% of the award will vest if the Company is in the top 55th percentile of ROIC among the BPG, and 175% of the award will vest if the Company is at or above the 85th percentile of ROIC among the BPG, as measured and determined by the Compensation Committee at the end of the Performance Period. Read SEC document |
| December 31, 2025 Filed Jan 5, 2026 20:18 UTC | Core Laboratories Inc. /DE/ CLB · Entity 5382 | Exercise / conversionPerformance Shares · Derivative | 24,952 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-002257 · ownership.xml · derivative · entry 5 Tattoli Mark Damian · CIK 0001872069 · SVP, Gen Counsel & Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 24,952 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: These shares were awarded as restricted performance shares in February 2023, as disclosed in the Reporting Person's Form 4 filing on February 21, 2023. The Company finished in the 68th percentile of return on invested capital among the Bloomberg Peer Group at the conclusion of the performance period on December 31, 2025. Therefore, the performance criteria and requirements for vesting have been satisfied at 116.5% of the target award level, and such number of shares vested on December 31, 2025. F1 · derivative.expiration_date: These shares were awarded as restricted performance shares in February 2023, as disclosed in the Reporting Person's Form 4 filing on February 21, 2023. The Company finished in the 68th percentile of return on invested capital among the Bloomberg Peer Group at the conclusion of the performance period on December 31, 2025. Therefore, the performance criteria and requirements for vesting have been satisfied at 116.5% of the target award level, and such number of shares vested on December 31, 2025. Read SEC document |
| December 31, 2025 Filed Jan 5, 2026 20:18 UTC | Core Laboratories Inc. /DE/ CLB · Entity 5382 | Exercise / conversionCommon Stock | 24,952 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-002257 · ownership.xml · nonDerivative · entry 2 Tattoli Mark Damian · CIK 0001872069 · SVP, Gen Counsel & Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,670.621 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 31, 2025 Filed Jan 5, 2026 20:18 UTC | Core Laboratories Inc. /DE/ CLB · Entity 5382 | Tax withholdingCommon Stock | 14,310 | $16.03 | $229,389.30 |
DisclosureSEC source: 0001193125-26-002257 · ownership.xml · nonDerivative · entry 1 Tattoli Mark Damian · CIK 0001872069 · SVP, Gen Counsel & Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,360.621 Read SEC document |
| October 01, 2025 Filed Oct 2, 2025 21:16 UTC | Core Laboratories Inc. /DE/ CLB · Entity 5382 | Exercise / conversionRestricted Shares · Derivative | 700 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-25-228649 · ownership.xml · derivative · entry 5 Tattoli Mark Damian · CIK 0001872069 · SVP, Gen Counsel & Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,450 Underlying: Common Stock · 700 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Restricted Shares vest annually over six years on the anniversary of the grant date in the amount specified in the award agreement, provided the reporting person remains in continuous service on each such vesting date. F1 · derivative.exercise_date: The Restricted Shares vest annually over six years on the anniversary of the grant date in the amount specified in the award agreement, provided the reporting person remains in continuous service on each such vesting date. F1 · derivative.expiration_date: The Restricted Shares vest annually over six years on the anniversary of the grant date in the amount specified in the award agreement, provided the reporting person remains in continuous service on each such vesting date. F2 · balance_after: Multiple restricted share grants are included in this total. Read SEC document |
| October 01, 2025 Filed Oct 2, 2025 21:16 UTC | Core Laboratories Inc. /DE/ CLB · Entity 5382 | Exercise / conversionCommon Stock | 700 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-25-228649 · ownership.xml · nonDerivative · entry 2 Tattoli Mark Damian · CIK 0001872069 · SVP, Gen Counsel & Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,994.621 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 01, 2025 Filed Oct 2, 2025 21:16 UTC | Core Laboratories Inc. /DE/ CLB · Entity 5382 | Tax withholdingCommon Stock | 276 | $12.58 | $3,472.08 |
DisclosureSEC source: 0001193125-25-228649 · ownership.xml · nonDerivative · entry 1 Tattoli Mark Damian · CIK 0001872069 · SVP, Gen Counsel & Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,718.621 Read SEC document |
| August 01, 2025 Filed Aug 5, 2025 13:21 UTC | Core Laboratories Inc. /DE/ CLB · Entity 5382 | Exercise / conversionRestricted Shares · Derivative | 250 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-102465 · ownership.xml · derivative · entry 5 Tattoli Mark Damian · CIK 0001872069 · SVP, Gen Counsel & Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,150 Underlying: Common Stock · 250 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Restricted Shares vest annually over six years on the anniversary of the grant date in the amount specified in the award agreement, provided the reporting person remains in continuous service on each such vesting date. F1 · derivative.exercise_date: The Restricted Shares vest annually over six years on the anniversary of the grant date in the amount specified in the award agreement, provided the reporting person remains in continuous service on each such vesting date. F1 · derivative.expiration_date: The Restricted Shares vest annually over six years on the anniversary of the grant date in the amount specified in the award agreement, provided the reporting person remains in continuous service on each such vesting date. F2 · balance_after: Multiple restricted share grants are included in this total. Read SEC document |
| August 01, 2025 Filed Aug 5, 2025 13:21 UTC | Core Laboratories Inc. /DE/ CLB · Entity 5382 | Exercise / conversionCommon Stock | 250 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-102465 · ownership.xml · nonDerivative · entry 2 Tattoli Mark Damian · CIK 0001872069 · SVP, Gen Counsel & Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,393.621 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 01, 2025 Filed Aug 5, 2025 13:21 UTC | Core Laboratories Inc. /DE/ CLB · Entity 5382 | Tax withholdingCommon Stock | 99 | $10.53 | $1,042.47 |
DisclosureSEC source: 0000950170-25-102465 · ownership.xml · nonDerivative · entry 1 Tattoli Mark Damian · CIK 0001872069 · SVP, Gen Counsel & Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,294.621 Read SEC document |
| May 01, 2025 Filed May 5, 2025 18:53 UTC | Core Laboratories Inc. /DE/ CLB · Entity 5382 | Exercise / conversionRestricted Shares · Derivative | 200 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-063437 · ownership.xml · derivative · entry 8 Tattoli Mark Damian · CIK 0001872069 · SVP, Gen Counsel & Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,650 Underlying: Common Stock · 200 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Restricted Shares vest annually over six years on the anniversary of the grant date in the amount specified in the award agreement, provided the reporting person remains in continuous service on each such vesting date. F1 · derivative.exercise_date: The Restricted Shares vest annually over six years on the anniversary of the grant date in the amount specified in the award agreement, provided the reporting person remains in continuous service on each such vesting date. F1 · derivative.expiration_date: The Restricted Shares vest annually over six years on the anniversary of the grant date in the amount specified in the award agreement, provided the reporting person remains in continuous service on each such vesting date. F2 · balance_after: Multiple restricted share grants are included in this total. Read SEC document |
| May 01, 2025 Filed May 5, 2025 18:53 UTC | Core Laboratories Inc. /DE/ CLB · Entity 5382 | Exercise / conversionRestricted Shares · Derivative | 250 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-063437 · ownership.xml · derivative · entry 7 Tattoli Mark Damian · CIK 0001872069 · SVP, Gen Counsel & Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,400 Underlying: Common Stock · 250 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Restricted Shares vest annually over six years on the anniversary of the grant date in the amount specified in the award agreement, provided the reporting person remains in continuous service on each such vesting date. F1 · derivative.exercise_date: The Restricted Shares vest annually over six years on the anniversary of the grant date in the amount specified in the award agreement, provided the reporting person remains in continuous service on each such vesting date. F1 · derivative.expiration_date: The Restricted Shares vest annually over six years on the anniversary of the grant date in the amount specified in the award agreement, provided the reporting person remains in continuous service on each such vesting date. F2 · balance_after: Multiple restricted share grants are included in this total. Read SEC document |
| May 01, 2025 Filed May 5, 2025 18:53 UTC | Core Laboratories Inc. /DE/ CLB · Entity 5382 | Exercise / conversionCommon Stock | 200 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-063437 · ownership.xml · nonDerivative · entry 4 Tattoli Mark Damian · CIK 0001872069 · SVP, Gen Counsel & Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,071.621 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 01, 2025 Filed May 5, 2025 18:53 UTC | Core Laboratories Inc. /DE/ CLB · Entity 5382 | Tax withholdingCommon Stock | 79 | $11.68 | $922.72 |
DisclosureSEC source: 0000950170-25-063437 · ownership.xml · nonDerivative · entry 3 Tattoli Mark Damian · CIK 0001872069 · SVP, Gen Counsel & Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,992.621 Read SEC document |
| May 01, 2025 Filed May 5, 2025 18:53 UTC | Core Laboratories Inc. /DE/ CLB · Entity 5382 | Exercise / conversionCommon Stock | 250 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-063437 · ownership.xml · nonDerivative · entry 2 Tattoli Mark Damian · CIK 0001872069 · SVP, Gen Counsel & Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,242.621 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 01, 2025 Filed May 5, 2025 18:53 UTC | Core Laboratories Inc. /DE/ CLB · Entity 5382 | Tax withholdingCommon Stock | 99 | $11.68 | $1,156.32 |
DisclosureSEC source: 0000950170-25-063437 · ownership.xml · nonDerivative · entry 1 Tattoli Mark Damian · CIK 0001872069 · SVP, Gen Counsel & Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,143.621 Read SEC document |
| February 13, 2025 Filed Feb 13, 2025 21:44 UTC | Core Laboratories Inc. /DE/ CLB · Entity 5382 | GrantPerformance Shares · Derivative | 32,912 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-019972 · ownership.xml · derivative · entry 1 Tattoli Mark Damian · CIK 0001872069 · SVP, Gen Counsel & Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,912 Underlying: Common Stock · 32,912 shares Expires not disclosed F1 · derivative.exercise_date: This award vests following the conclusion of a three-year performance period that began on January 1, 2025 and ends on December 31, 2027 (the "Performance Period"). This award survives termination of employment due to death, disability, termination by the Company without cause or retirement by the employee upon having reached 62 years of age. In all cases, the shares will vest, if at all, on January 1, 2028, following the conclusion of the Performance Period as follows: 50% of the award will vest if the Company is in the top 35th percentile of Return on Invested Capital ("ROIC") among the Bloomberg Peer Group ("BPG"), 100% of the award will vest if the Company is in the top 55th percentile of ROIC among the BPG, and 175% of the award will vest if the Company is at or above the 85th percentile of ROIC among the BPG, as measured and determined by the Compensation Committee at the end of the Performance Period. F2 · derivative.exercise_date: The number of common shares vesting pursuant to the award will be interpolated on a straight-line basis between the 35th and 55th percentile of ROIC (equivalent to 50% up to 100% of the award) and again between the 55th and 85th percentile of ROIC (equivalent to 100% up to 175% of the award). The number of common shares that could vest over 100% of the award up to the maximum of 175% of the award, if any, will be reduced by one-half if absolute total shareholder return for the Performance Period is negative, as measured and determined by the Compensation Committee at the end of the Performance Period. F1 · derivative.expiration_date: This award vests following the conclusion of a three-year performance period that began on January 1, 2025 and ends on December 31, 2027 (the "Performance Period"). This award survives termination of employment due to death, disability, termination by the Company without cause or retirement by the employee upon having reached 62 years of age. In all cases, the shares will vest, if at all, on January 1, 2028, following the conclusion of the Performance Period as follows: 50% of the award will vest if the Company is in the top 35th percentile of Return on Invested Capital ("ROIC") among the Bloomberg Peer Group ("BPG"), 100% of the award will vest if the Company is in the top 55th percentile of ROIC among the BPG, and 175% of the award will vest if the Company is at or above the 85th percentile of ROIC among the BPG, as measured and determined by the Compensation Committee at the end of the Performance Period. Read SEC document |
| December 31, 2024 Filed Jan 3, 2025 21:56 UTC | Core Laboratories Inc. /DE/ CLB · Entity 5382 | Exercise / conversionPerformance Shares · Derivative | 9,604 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-001310 · ownership.xml · derivative · entry 5 Tattoli Mark Damian · CIK 0001872069 · SVP, Gen Counsel & Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 9,604 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: These shares were awarded as restricted performance shares in February 2022, as disclosed in the Reporting Person's Form 4 filing on February 17, 2022. The Company finished in the 52nd percentile of return on invested capital among the Bloomberg Peer Group at the conclusion of the performance period on December 31, 2024. Therefore, the performance criteria and requirements for vesting have been satisfied at 54.6% of the target award level, and such number of shares vested on December 31, 2024. F1 · derivative.expiration_date: These shares were awarded as restricted performance shares in February 2022, as disclosed in the Reporting Person's Form 4 filing on February 17, 2022. The Company finished in the 52nd percentile of return on invested capital among the Bloomberg Peer Group at the conclusion of the performance period on December 31, 2024. Therefore, the performance criteria and requirements for vesting have been satisfied at 54.6% of the target award level, and such number of shares vested on December 31, 2024. Read SEC document |
| December 31, 2024 Filed Jan 3, 2025 21:56 UTC | Core Laboratories Inc. /DE/ CLB · Entity 5382 | Exercise / conversionCommon Stock | 9,604 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-001310 · ownership.xml · nonDerivative · entry 2 Tattoli Mark Damian · CIK 0001872069 · SVP, Gen Counsel & Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,899.621 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 31, 2024 Filed Jan 3, 2025 21:56 UTC | Core Laboratories Inc. /DE/ CLB · Entity 5382 | Tax withholdingCommon Stock | 5,028 | $17.31 | $87,034.68 |
DisclosureSEC source: 0000950170-25-001310 · ownership.xml · nonDerivative · entry 1 Tattoli Mark Damian · CIK 0001872069 · SVP, Gen Counsel & Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,871.621 Read SEC document |
| October 01, 2024 Filed Oct 3, 2024 18:13 UTC | Core Laboratories Inc. /DE/ CLB · Entity 5382 | Exercise / conversionRestricted Shares · Derivative | 700 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-112230 · ownership.xml · derivative · entry 5 Tattoli Mark Damian · CIK 0001872069 · SVP, Gen Counsel & Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,850 Underlying: Common Stock · 700 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Restricted Shares vest annually over six years on the anniversary of the grant date in the amount of 1/6th of the grant total, provided the reporting person remains in continuous service on each such vesting date. F1 · derivative.exercise_date: The Restricted Shares vest annually over six years on the anniversary of the grant date in the amount of 1/6th of the grant total, provided the reporting person remains in continuous service on each such vesting date. F1 · derivative.expiration_date: The Restricted Shares vest annually over six years on the anniversary of the grant date in the amount of 1/6th of the grant total, provided the reporting person remains in continuous service on each such vesting date. F2 · balance_after: Multiple restricted share grants are included in this total. Read SEC document |
| October 01, 2024 Filed Oct 3, 2024 18:13 UTC | Core Laboratories Inc. /DE/ CLB · Entity 5382 | Exercise / conversionCommon Stock | 700 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-112230 · ownership.xml · nonDerivative · entry 2 Tattoli Mark Damian · CIK 0001872069 · SVP, Gen Counsel & Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,571.621 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 01, 2024 Filed Oct 3, 2024 18:13 UTC | Core Laboratories Inc. /DE/ CLB · Entity 5382 | Tax withholdingCommon Stock | 276 | $19.21 | $5,301.96 |
DisclosureSEC source: 0000950170-24-112230 · ownership.xml · nonDerivative · entry 1 Tattoli Mark Damian · CIK 0001872069 · SVP, Gen Counsel & Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,295.621 Read SEC document |
| August 01, 2024 Filed Aug 5, 2024 17:06 UTC | Core Laboratories Inc. /DE/ CLB · Entity 5382 | Exercise / conversionRestricted Shares · Derivative | 120 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-090555 · ownership.xml · derivative · entry 8 Tattoli Mark Damian · CIK 0001872069 · SVP, Gen Counsel & Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,800 Underlying: Common Stock · 120 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Restricted Shares vest annually over six years on the anniversary of the grant date in the amount of 1/6th of the grant total, provided the reporting person remains in continuous service on each such vesting date. F1 · derivative.exercise_date: The Restricted Shares vest annually over six years on the anniversary of the grant date in the amount of 1/6th of the grant total, provided the reporting person remains in continuous service on each such vesting date. F1 · derivative.expiration_date: The Restricted Shares vest annually over six years on the anniversary of the grant date in the amount of 1/6th of the grant total, provided the reporting person remains in continuous service on each such vesting date. F2 · balance_after: Multiple restricted share grants are included in this total. Read SEC document |
| August 01, 2024 Filed Aug 5, 2024 17:06 UTC | Core Laboratories Inc. /DE/ CLB · Entity 5382 | Exercise / conversionRestricted Shares · Derivative | 250 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-090555 · ownership.xml · derivative · entry 7 Tattoli Mark Damian · CIK 0001872069 · SVP, Gen Counsel & Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,550 Underlying: Common Stock · 250 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Restricted Shares vest annually over six years on the anniversary of the grant date in the amount of 1/6th of the grant total, provided the reporting person remains in continuous service on each such vesting date. F1 · derivative.exercise_date: The Restricted Shares vest annually over six years on the anniversary of the grant date in the amount of 1/6th of the grant total, provided the reporting person remains in continuous service on each such vesting date. F1 · derivative.expiration_date: The Restricted Shares vest annually over six years on the anniversary of the grant date in the amount of 1/6th of the grant total, provided the reporting person remains in continuous service on each such vesting date. F2 · balance_after: Multiple restricted share grants are included in this total. Read SEC document |
| August 01, 2024 Filed Aug 5, 2024 17:06 UTC | Core Laboratories Inc. /DE/ CLB · Entity 5382 | Exercise / conversionCommon Stock | 120 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-090555 · ownership.xml · nonDerivative · entry 4 Tattoli Mark Damian · CIK 0001872069 · SVP, Gen Counsel & Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,768.621 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 01, 2024 Filed Aug 5, 2024 17:06 UTC | Core Laboratories Inc. /DE/ CLB · Entity 5382 | Tax withholdingCommon Stock | 48 | $23.24 | $1,115.52 |
DisclosureSEC source: 0000950170-24-090555 · ownership.xml · nonDerivative · entry 3 Tattoli Mark Damian · CIK 0001872069 · SVP, Gen Counsel & Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,720.621 Read SEC document |
| August 01, 2024 Filed Aug 5, 2024 17:06 UTC | Core Laboratories Inc. /DE/ CLB · Entity 5382 | Exercise / conversionCommon Stock | 250 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-090555 · ownership.xml · nonDerivative · entry 2 Tattoli Mark Damian · CIK 0001872069 · SVP, Gen Counsel & Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,970.621 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 01, 2024 Filed Aug 5, 2024 17:06 UTC | Core Laboratories Inc. /DE/ CLB · Entity 5382 | Tax withholdingCommon Stock | 99 | $23.24 | $2,300.76 |
DisclosureSEC source: 0000950170-24-090555 · ownership.xml · nonDerivative · entry 1 Tattoli Mark Damian · CIK 0001872069 · SVP, Gen Counsel & Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,871.621 Read SEC document |
| May 01, 2024 Filed May 2, 2024 20:59 UTC | Core Laboratories Inc. /DE/ CLB · Entity 5382 | Exercise / conversionRestricted Shares · Derivative | 200 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-052284 · ownership.xml · derivative · entry 8 Tattoli Mark Damian · CIK 0001872069 · SVP, Gen Counsel & Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,170 Underlying: Common Stock · 200 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Restricted Shares vest annually over six years on the anniversary of the grant date in the amount of 1/6th of the grant total, provided the reporting person remains in continuous service on each such vesting date. F1 · derivative.exercise_date: The Restricted Shares vest annually over six years on the anniversary of the grant date in the amount of 1/6th of the grant total, provided the reporting person remains in continuous service on each such vesting date. F1 · derivative.expiration_date: The Restricted Shares vest annually over six years on the anniversary of the grant date in the amount of 1/6th of the grant total, provided the reporting person remains in continuous service on each such vesting date. F2 · balance_after: Multiple restricted share grants are included in this total. Read SEC document |
| May 01, 2024 Filed May 2, 2024 20:59 UTC | Core Laboratories Inc. /DE/ CLB · Entity 5382 | Exercise / conversionRestricted Shares · Derivative | 250 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-052284 · ownership.xml · derivative · entry 7 Tattoli Mark Damian · CIK 0001872069 · SVP, Gen Counsel & Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,920 Underlying: Common Stock · 250 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Restricted Shares vest annually over six years on the anniversary of the grant date in the amount of 1/6th of the grant total, provided the reporting person remains in continuous service on each such vesting date. F1 · derivative.exercise_date: The Restricted Shares vest annually over six years on the anniversary of the grant date in the amount of 1/6th of the grant total, provided the reporting person remains in continuous service on each such vesting date. F1 · derivative.expiration_date: The Restricted Shares vest annually over six years on the anniversary of the grant date in the amount of 1/6th of the grant total, provided the reporting person remains in continuous service on each such vesting date. F2 · balance_after: Multiple restricted share grants are included in this total. Read SEC document |
| May 01, 2024 Filed May 2, 2024 20:59 UTC | Core Laboratories Inc. /DE/ CLB · Entity 5382 | Exercise / conversionCommon Stock | 200 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-052284 · ownership.xml · nonDerivative · entry 4 Tattoli Mark Damian · CIK 0001872069 · SVP, Gen Counsel & Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,576.621 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 01, 2024 Filed May 2, 2024 20:59 UTC | Core Laboratories Inc. /DE/ CLB · Entity 5382 | Tax withholdingCommon Stock | 79 | $15.71 | $1,241.09 |
DisclosureSEC source: 0000950170-24-052284 · ownership.xml · nonDerivative · entry 3 Tattoli Mark Damian · CIK 0001872069 · SVP, Gen Counsel & Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,497.621 Read SEC document |
| May 01, 2024 Filed May 2, 2024 20:59 UTC | Core Laboratories Inc. /DE/ CLB · Entity 5382 | Exercise / conversionCommon Stock | 250 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-052284 · ownership.xml · nonDerivative · entry 2 Tattoli Mark Damian · CIK 0001872069 · SVP, Gen Counsel & Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,747.621 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 01, 2024 Filed May 2, 2024 20:59 UTC | Core Laboratories Inc. /DE/ CLB · Entity 5382 | Tax withholdingCommon Stock | 99 | $15.71 | $1,555.29 |
DisclosureSEC source: 0000950170-24-052284 · ownership.xml · nonDerivative · entry 1 Tattoli Mark Damian · CIK 0001872069 · SVP, Gen Counsel & Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,648.621 Read SEC document |
| February 15, 2024 Filed Feb 15, 2024 21:10 UTC | Core Laboratories Inc. /DE/ CLB · Entity 5382 | GrantPerformance Shares · Derivative | 38,002 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-015883 · ownership.xml · derivative · entry 1 Tattoli Mark Damian · CIK 0001872069 · SVP, Gen Counsel & Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,002 Underlying: Common Stock · 38,002 shares Expires not disclosed F1 · derivative.exercise_date: This award vests at the end of a three-year performance period that began on January 1, 2024 and ends on December 31, 2026 (the "Performance Period"). This award survives termination of employment due to death, disability, termination by the Company without cause or retirement by the employee upon having reached 62 years of age. In all cases, the shares will vest, if at all, at the end of the Performance Period as follows: 50% of the award will vest if the Company is in the top 35th percentile of Return on Invested Capital (ROIC) among the Bloomberg Peer Group (BPG), 100% of the award will vest if the Company is in the top 55th percentile of ROIC of the BPG, and 175% of the award will vest if the Company is in the top 85th percentile of ROIC of the BPG, as measured and determined by the Compensation Committee at the end of the Performance Period. F2 · derivative.exercise_date: The number of common shares vesting pursuant to the award will be interpolated on a straight-line basis between the 35th and 55th percentile (equivalent to 50% up to 100% of the award) and again between the 55th and 85th percentile (equivalent to 100% up to 175% of the award). The number of common shares that could vest over 100% of the award up to the maximum of 175% of the award, if any, will be reduced by one-half if absolute total shareholder return for the Performance Period is negative, as measured and determined by the Compensation Committee at the end of the Performance Period. F1 · derivative.expiration_date: This award vests at the end of a three-year performance period that began on January 1, 2024 and ends on December 31, 2026 (the "Performance Period"). This award survives termination of employment due to death, disability, termination by the Company without cause or retirement by the employee upon having reached 62 years of age. In all cases, the shares will vest, if at all, at the end of the Performance Period as follows: 50% of the award will vest if the Company is in the top 35th percentile of Return on Invested Capital (ROIC) among the Bloomberg Peer Group (BPG), 100% of the award will vest if the Company is in the top 55th percentile of ROIC of the BPG, and 175% of the award will vest if the Company is in the top 85th percentile of ROIC of the BPG, as measured and determined by the Compensation Committee at the end of the Performance Period. F2 · derivative.expiration_date: The number of common shares vesting pursuant to the award will be interpolated on a straight-line basis between the 35th and 55th percentile (equivalent to 50% up to 100% of the award) and again between the 55th and 85th percentile (equivalent to 100% up to 175% of the award). The number of common shares that could vest over 100% of the award up to the maximum of 175% of the award, if any, will be reduced by one-half if absolute total shareholder return for the Performance Period is negative, as measured and determined by the Compensation Committee at the end of the Performance Period. Read SEC document |
| December 31, 2023 Filed Jan 3, 2024 22:50 UTC | Core Laboratories Inc. /DE/ CLB · Entity 5382 | Exercise / conversionCommon Stock | 6,900 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-001250 · ownership.xml · nonDerivative · entry 2 Tattoli Mark Damian · CIK 0001872069 · SVP, Gen Counsel & Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,092.621 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 31, 2023 Filed Jan 3, 2024 22:50 UTC | Core Laboratories Inc. /DE/ CLB · Entity 5382 | Tax withholdingCommon Stock | 2,654 | $17.66 | $46,869.64 |
DisclosureSEC source: 0000950170-24-001250 · ownership.xml · nonDerivative · entry 1 Tattoli Mark Damian · CIK 0001872069 · SVP, Gen Counsel & Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,438.621 Read SEC document |
| December 31, 2023 Filed Jan 8, 2024 19:50 UTC Amendment | Core Laboratories Inc. /DE/ CLB · Entity 5382 | Tax withholdingCommon Stock | 2,716 | $17.66 | $47,964.56 |
DisclosureSEC source: 0000950170-24-002893 · ownership.xml · nonDerivative · entry 1 Tattoli Mark Damian · CIK 0001872069 · SVP, Gen Counsel & Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,376.621 F1 · shares: The original Form 4, filed on January 3, 2024, is being amended by this Form 4 amendment to correct an administrative error of the issuer, whereupon the number of shares withheld to satisfy tax withholding obligations upon vesting of certain restricted performance shares was misreported as 2,654 shares. The corrected transaction reflects an increase of 62 shares withheld by the issuer as a result such vesting and a corresponding reduction in the number of shares beneficially owned by the reporting person. Read SEC document |
| December 29, 2023 Filed Jan 3, 2024 22:50 UTC | Core Laboratories Inc. /DE/ CLB · Entity 5382 | Exercise / conversionPerformance Shares · Derivative | 6,900 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-001250 · ownership.xml · derivative · entry 5 Tattoli Mark Damian · CIK 0001872069 · SVP, Gen Counsel & Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,900 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: These shares were awarded as restricted performance shares in February 2021, as disclosed in the Reporting Person's Form 4A filing on October 6, 2021. All requirements for 100% vesting have been met and thus the restricted shares vested on December 31, 2023 at the conclusion of the performance period. F1 · derivative.expiration_date: These shares were awarded as restricted performance shares in February 2021, as disclosed in the Reporting Person's Form 4A filing on October 6, 2021. All requirements for 100% vesting have been met and thus the restricted shares vested on December 31, 2023 at the conclusion of the performance period. Read SEC document |
| December 01, 2023 Filed Dec 4, 2023 21:54 UTC | Core Laboratories Inc. /DE/ CLB · Entity 5382 | Exercise / conversionRestricted Shares · Derivative | 160 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-23-067809 · ownership.xml · derivative · entry 5 Tattoli Mark Damian · CIK 0001872069 · SVP, Gen Counsel & Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,370 Underlying: Common Stock · 160 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Restricted Shares vest annually over six years on the anniversary of the grant date in the amount of 1/6th of the grant total, provided the reporting person remains in continuous service on each such vesting date. F1 · derivative.exercise_date: The Restricted Shares vest annually over six years on the anniversary of the grant date in the amount of 1/6th of the grant total, provided the reporting person remains in continuous service on each such vesting date. F1 · derivative.expiration_date: The Restricted Shares vest annually over six years on the anniversary of the grant date in the amount of 1/6th of the grant total, provided the reporting person remains in continuous service on each such vesting date. F2 · balance_after: Multiple restricted share grants are included in this total. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.